Eli Lilly ·
Eli Lilly sued Ro (Roman Pharmaceuticals and related entities) in mid-2025, challenging Ro's compounded GLP-1 program and the relationship between Ro and its affiliated compounding pharmacies. The complaint alleged that Ro and its pharmacy partners effectively functioned as a unified drug distributor selling an unapproved copy of branded tirzepatide and that marketing claims misrepresented the nature, source, and equivalence of the compounded product. Ro has filed vigorous defenses, including challenges to standing and arguments that the First Amendment protects truthful commercial speech about legitimate compounded products. The case is actively being litigated.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.